TuHURA Biosciences, Inc. (HURA)
2.04
-0.01
(-0.49%)
USD |
NASDAQ |
Sep 24, 09:53
TuHURA Biosciences Enterprise Value : 133.84M for Sept. 23, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 23, 2026 | 133.84M |
| September 22, 2026 | 138.93M |
| September 21, 2026 | 142.12M |
| September 18, 2026 | 137.02M |
| September 17, 2026 | 136.39M |
| September 16, 2026 | 132.56M |
| September 15, 2026 | 132.56M |
| September 14, 2026 | 133.84M |
| September 11, 2026 | 133.84M |
| September 10, 2026 | 132.56M |
| September 09, 2026 | 131.29M |
| September 08, 2026 | 138.30M |
| September 04, 2026 | 139.57M |
| September 03, 2026 | 137.02M |
| September 02, 2026 | 136.39M |
| September 01, 2026 | 132.56M |
| August 31, 2026 | 138.93M |
| August 28, 2026 | 137.66M |
| August 27, 2026 | 138.93M |
| August 26, 2026 | 138.93M |
| August 25, 2026 | 133.20M |
| August 24, 2026 | 140.21M |
| August 21, 2026 | 130.65M |
| August 20, 2026 | 144.66M |
| August 19, 2026 | 148.49M |
| Date | Value |
|---|---|
| August 18, 2026 | 140.84M |
| August 17, 2026 | 148.49M |
| August 14, 2026 | 160.59M |
| August 13, 2026 | 149.76M |
| August 12, 2026 | 152.31M |
| August 11, 2026 | 149.76M |
| August 10, 2026 | 140.21M |
| August 07, 2026 | 138.93M |
| August 06, 2026 | 137.98M |
| August 05, 2026 | 136.39M |
| August 04, 2026 | 136.39M |
| August 03, 2026 | 139.57M |
| July 31, 2026 | 141.48M |
| July 30, 2026 | 141.48M |
| July 29, 2026 | 133.20M |
| July 28, 2026 | 138.93M |
| July 27, 2026 | 144.03M |
| July 24, 2026 | 137.66M |
| July 23, 2026 | 140.21M |
| July 22, 2026 | 145.94M |
| July 21, 2026 | 144.03M |
| July 20, 2026 | 145.94M |
| July 17, 2026 | 146.58M |
| July 16, 2026 | 144.66M |
| July 15, 2026 | 148.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.495B |
| Alnylam Pharmaceuticals, Inc. | 32.65B |
| Anika Therapeutics, Inc. | 259.52M |
| Savara, Inc. | 884.37M |
| Vericel Corp. | 1.917B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.223M |
| Total Expenses (Quarterly) | 9.223M |
| EPS Diluted (Quarterly) | -0.1442 |
| Earnings Yield | -26.14% |
| Normalized Earnings Yield | -27.43 |